Cyanotech (CYAN) Stock Price, News & Analysis

Company Overview

Cyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.

Key Stats

• Today's Range: $0.39 to $0.39
• 50-Day Range: $0.29 to $0.45
• 52-Week Range: $0.21 to $0.57
• Volume: N/A
• Average Volume: 1,410 shs
• Market Capitalization: $2.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CYAN Stock Analysis - Frequently Asked Questions

How have CYAN shares performed this year?

Cyanotech's stock was trading at $0.45 at the beginning of 2026. Since then, CYAN stock has decreased by 13.5% and is now trading at $0.3891.

How were Cyanotech's earnings last quarter?

Cyanotech Co. (OTCMKTS:CYAN) announced its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.16) earnings per share for the quarter. The biotechnology company earned $5.85 million during the quarter. Cyanotech had a negative trailing twelve-month return on equity of 20.62% and a negative net margin of 7.03%.

How do I buy shares of Cyanotech?

Shares of CYAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cyanotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyanotech investors own include AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Karyopharm Therapeutics (KPTI) and Madrigal Pharmaceuticals (MDGL).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 5/07/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medicinals & botanicals
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CYAN
• CIK: 768408
• Web: www.cyanotech.com
• Phone: (808) 326-1353
• Fax: 808-329-4533
• Employees: 95
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.20 million
• Net Margins: -7.03%
• Pretax Margin: -7.00%
• Return on Equity: -20.62%
• Return on Assets: -7.52%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 1.00
• Quick Ratio: 0.30

Sales & Book Value

• Annual Sales: $24.22 million
• Price / Sales: 0.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.23 per share
• Price / Book: 0.32

Miscellaneous

• Outstanding Shares: 7,390,000
• Free Float: 4,849,000
• Market Cap: $2.88 million
• Optionable: Not Optionable
• Beta: 0.17